UNITY Biotechnology, Inc.’s lead product, UBX0101, has hit the buffers in a Phase II osteoarthritis trial, raising some concern over the viability of its anti-aging thesis.
The 183-patient study found no difference between the p53/MDM2 interaction inhibitor and placebo in patients with moderate-to-severe painful osteoarthritis (OA) of the knee. None of the drug doses tested showed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?